Julia Post advises biotechnology, pharmaceutical, medical device, and trade association clients on a variety of federal and state regulatory and compliance matters. In particular, Ms. Post has experience in areas including biosimilars and interpretation and implementation of the Biologics Price Competition and Innovation Act of 2009; human cells, tissues, and cellular and tissue-based products (HCT/Ps); market exclusivity; informed consent requirements; and pharmacy substitution practices.
Prior to joining the Food and Drug practice group, Ms. Post was a member of the Litigation practice group where she focused on representing clients in Hatch-Waxman patent litigation.
